The Limited Times

Now you can see non-English news...

Biontech reports $ 480 million in sales

2021-03-30T11:28:31.197Z


Mainly thanks to the coronavirus vaccine, the Mainz biotech company was able to more than quadruple its sales. Now the group wants to expand its production capacities.


Enlarge image

Biontech headquarters in Mainz

Photo: UJ Alexander / imago images

The development of a coronavirus vaccine has brought the Mainz biotechnology company Biontech a solid increase in sales: For the past year, the Mainz biotechnology company expects sales of 482.3 million euros - after only around 108.6 million euros in the previous year.

The bottom line was a profit of 15 million euros.

So far, Biontech has shipped more than 200 million vaccine doses.

Orders for 1.4 million cans are on the books for 2021.

Now Biontech and its partner Pfizer want to produce more Covid-19 vaccine in 2021 than previously planned.

Biontech is now assuming a production capacity of up to 2.5 billion vaccine doses, announced the Mainz biotech company.

Most recently, the two partners had raised their production target to 2.3 to 2.4 from the previous two billion cans.

The increase was mainly made possible by improved manufacturing processes, the new Biontech production facility in Marburg, the approval of the withdrawal of a sixth vaccination dose and the expansion of the manufacturer and supplier network.

Biontech is holding further discussions with potential partners.

As of March 23, more than 200 million doses of the vaccine had been delivered worldwide.

More soon on SPIEGEL.de

apr / Reuters

Source: spiegel

All business articles on 2021-03-30

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.